Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $45.14

Oculis Holding AG (NASDAQ:OCS) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $49.3750.

OCS has been the topic of a number of recent research reports. Guggenheim initiated coverage on shares of Oculis in a research note on Wednesday. They set a “buy” rating and a $75.00 price target on the stock. Needham & Company LLC boosted their price target on shares of Oculis from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Stifel Nicolaus boosted their price target on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Wall Street Zen lowered shares of Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, HC Wainwright boosted their price target on shares of Oculis from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th.

Institutional Trading of Oculis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its stake in shares of Oculis by 9.1% during the first quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock worth $1,855,000 after buying an additional 5,813 shares during the period. Himension Capital Singapore PTE. LTD. purchased a new stake in shares of Oculis during the first quarter worth approximately $503,000. Koshinski Asset Management Inc. purchased a new stake in shares of Oculis during the first quarter worth approximately $238,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Oculis during the first quarter worth approximately $776,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of Oculis during the fourth quarter worth approximately $9,862,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Trading Down 0.2%

NASDAQ OCS opened at $27.91 on Friday. The firm’s 50-day moving average is $27.39 and its two-hundred day moving average is $24.74. Oculis has a 12 month low of $16.00 and a 12 month high of $34.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The stock has a market capitalization of $1.62 billion, a P/E ratio of -13.10 and a beta of 0.38.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. On average, sell-side analysts anticipate that Oculis will post -2.18 earnings per share for the current year.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.